A Multi-center, Multi-dose Phase Ib/IIa Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy, Pharmacokinetics, and Impact on Biomarkers of IPG11406 in Patients With Lupus Nephritis
Latest Information Update: 15 Jan 2026
At a glance
- Drugs IPG 11406 (Primary)
- Indications Lupus nephritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Immunophage Biotech
Most Recent Events
- 17 Dec 2025 Planned primary completion date changed from 12 Nov 2025 to 22 Apr 2026.
- 10 Feb 2025 Planned initiation date changed from 31 Dec 2024 to 20 Feb 2025.
- 10 Feb 2025 Status changed from not yet recruiting to recruiting.